Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Rating Upgraded by Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biodexa Pharmaceuticals currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 2.1%

BDRX stock opened at $0.70 on Friday. Biodexa Pharmaceuticals has a twelve month low of $0.68 and a twelve month high of $19.40. The stock has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $4.07.

Shares of Biodexa Pharmaceuticals are scheduled to reverse split on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.